explore -WSS

explore

author：fashion 2025-08-20 18:41:14 - browse：46261

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

WSS

Address the ethical violations that led to 'Three Identical Strangers'

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Telehealth options flood the market as retailers push virtual care

Telehealth options flood the market as retailers push virtual care

How one patient went off dialysis — and others can too

leisure time

explore

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Listen: Who gets the credit for GLP

Heart attack and stroke risk calculators need revising

Senate panel to vote on hospitals, PBMs, prisoner care

Supreme Court strikes down use of affirmative action

Readout Newsletter: What happened with Sarepta's Duchenne data

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Did you have Obamacare on your GOP debate bingo card?

Novavax promises a turnaround & Lilly roils the obesity market

Inequities make cancer less preventable for women: report

hotspot

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

After a drawn out lobbying fight, ARPA

Telehealth options flood the market as retailers push virtual care

Paying for Covid pills will soon shift to insurers

Maker of FluMist seeks to allow at

Inequities make cancer less preventable for women: report

explore

focus

hotspot

knowledge